C2i Genomics is a privately-owned company, headquartered in NYC with an R&D center in Israel. The company provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. The company's ultra-sensitive liquid biopsy assay will allow physicians to monitor patient treatment response and detect treatment failure or disease recurrence months and potentially years earlier than current monitoring methods.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/09/20 | $12,000,000 | Series A |
Casdin Capital NFX Capital The Mark Foundation for Cancer Research | undisclosed |
